Comparative Pharmacology
Head-to-head clinical analysis: NERLYNX versus PONATINIB HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NERLYNX versus PONATINIB HYDROCHLORIDE.
NERLYNX vs PONATINIB HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neratinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that inhibits EGFR, HER2, and HER4, leading to reduced downstream signaling and cell proliferation.
Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.
NERLYNX (neratinib) 240 mg (6 tablets of 40 mg) orally once daily with food for a total duration of 1 year.
45 mg orally once daily with or without food.
None Documented
None Documented
Terminal half-life approximately 7–17 days (mean ~9 days) after a 240 mg daily dose, supporting once-daily dosing. Steady state reached by ~4–6 weeks.
Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days.
Primarily hepatic metabolism; 97% of dose recovered in feces (including unchanged drug and metabolites), <1% in urine as unchanged drug. Biliary excretion is a major route.
Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor